IDT will operate as a standalone company within Danaher's Life Sciences segment after the close of the deal, which is expected to occur in mid-2018.
Aldevron will manufacture IDT's patented S. pyogenes HiFi Cas9 mutant for research, clinical, and commercial uses.
The companies will develop a portfolio of indexed adapters specifically designed for multiplex NGS and optimized for use on Illumina systems such as the NovaSeq.
The agreement provides researchers with local customer care, and allows them to order reagents from within the country rather than importing them.
The technology has been a core capability of the firm, which is expanding its suite of products to address the broader needs of genomics researchers.
The acquisition of GeneWorks' oligo business widens IDT's reach in the Asia-Pacific region, the company said.
IDT has licensed the CRISPR/Cpf1 RNA-guided editing system from the Broad Institute and intends to sell it to pharmaceutical and other commercial labs.
The Hereditary Cancer Solution combines target capture probes from Integrated DNA Technologies with specialized analytics developed by Sophia.
The acquisition of San Diego-based ValueGene expands IDT's presence in Southern California.
The companies will combine their respective technologies and expertise to develop new products for low-input, targeted RNA-seq applications.
Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.
CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.
The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.
In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.